NeuroCircuit Therapeutics is a privately held biopharmaceutical company focused on developing novel treatments for CNS diseases.

Our lead program is focused on Down Syndrome.

Down Syndrome is the leading genetic cause of intellectual disability and brain dysfunction and affects > 400,000 people in the USA. Through our research and development, we hope to improve the lives of those impacted by down syndrome both in the USA and around the world.

Over time, our goal is to improve the lives of patients and caregivers across a broad range of CNS diseases.